Impact of Anti-Androgen Therapies on COVID-19 Susceptibility: A Case-Control Study in Male Population from Two COVID-19 Regional Centers of Lombardy, Italy

    Massimo Lazzeri, Stefano Duga, Elena Azzolini … Rosanna Asselta

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary This case-control study from Lombardy, Italy, observed that men over 55 taking 5-alpha reductase inhibitors for benign prostatic hyperplasia were hospitalized for COVID-19 at a lower rate than age-matched controls, suggesting potential protective effects against severe disease.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on medrxiv.org →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Human Type 3 5α-Reductase Is Expressed in Peripheral Tissues at Higher Levels Than Types 1 and 2 and Its Activity Is Potently Inhibited by Finasteride and Dutasteride Hormone Molecular Biology and Clinical Investigation · 2010

    Related research 3

    1. Change in Hair Growth-Related Gene Expression Profile in Human Isolated Hair Follicles Induced by 5-Alpha Reductase Inhibitors – Dutasteride and Finasteride – in the Presence of Testosterone Singapore Medical Journal · 2021
    2. What Do We Know About 5-Alpha Reductase Inhibitors? Surgical and Cosmetic Dermatology · 2018
    3. 5 Alpha-Reductase Inhibitors: What's New? Current opinion in urology · 2003